A Phase 1 Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Full Title

Purpose

Researchers are assessing the combination of teclistamab and mezigdomide to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing after treatment.

Teclistamab works by binding to proteins on cancer cells and immune cells (T cells) at the same time. This helps encourage your immune system to attack cancer cells and destroy them. It is given as a subcutaneous (under the skin) injection.

Mezigdomide works by targeting proteins that help keep myeloma cells alive. By destroying these proteins, mezigdomide may cause myeloma cells to die. This drug can also strengthen the immune system (T cells), to help teclistamab work better. Mezigdomide is taken orally (by mouth).

Combining teclistamab and mezigdomide may work better than either drug given alone.

Who Can Join

To join this study, there are a few conditions. You must:

• Have multiple myeloma that came back or keeps growing after at least 2 prior regimens of therapy.
• Have recovered from the serious side effects of prior treatments before getting the study therapy.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Malin Hultcrantz’s office at 646-608-3714.